Sudeep Pharma
- Market cap
- ₹ 10,901 Cr.
- P/E
- 69.2x
- P/B
- 12.3x
- 52-week range
- 524.05 – 1,378
- ROE
- 25%
- ROCE
- 28%
- Dividend yield
- 0.2%
- Debt / equity
- 0.17
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Sudeep Pharma Private Limited is an India-based manufacturing pharmaceutical and nutraceutical products company. The Company is engaged in business of manufacturing and selling pharmaceutical and food, nutrition and specialty ingredients and intermediaries, used by pharmaceutical, food and nutrition industries globally. The Company a wide range of products, including mineral salts such as calcium salts, zinc salts, iron salts, potassium salts, magnesium salts, sodium salts, simethicone salts and copper salts. It offers products to a wide range of markets, which includes pharmaceuticals, dietary health, infant nutrition, beverage, dairy products, bakery products, confectionery, and staple food markets. Its subsidiaries include Sudeep Nutrition Private Limited, Sudeep Pharma USA Inc., Sudeep Pharma B.V., and Sudeep Advanced Materials Private Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Sudeep Pharma against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)69.2 against a typical 34.3: pricier than most peers (1st = cheapest).173rd of 220
- Sales growth+26.4% against a typical +15.6% from a year earlier.64th of 197
- Profit growth+32.3% against a typical +18.9% from a year earlier.66th of 160
- Share price, 3 months+27.9% against a typical −0.5%.25th of 200
- Size₹ 10,901 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).39th of 199
Latest announcements
Exchange filings and their impact on the company.
- FDA approval unlocks 51,200 MT greenfield plant, with commercial sales from H2 FY27 after customer qualification.
Sudeep Pharma received Gujarat FDA approval to start manufacturing at its new greenfield facility at 179 Nandesari, Gujarat, with annual capacity of 51,200 MT. About 60% is for existing pharma, food and nutrition products and the rest for newer phosphates, glycinates, gluconates, citrates including high-value bisglycinates constrained at the old plant. Commercial supplies are expected from H2 FY27 after customer qualification, enabling the company to serve domestic and international demand and pursue larger regulated-market opportunities.
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 28 Oct 2026Upcoming | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2026 and other business matters |
| 4 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 21 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| 6 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 19 Dec 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 149 | 116 | 158 | 125 | 163 | 172 | 182 | 158 |
| Expenses | 85 | 76 | 99 | 81 | 107 | 112 | 120 | 103 |
| Operating Profit | 63 | 39 | 59 | 44 | 55 | 60 | 63 | 55 |
| OPM % | 43% | 34% | 37% | 35% | 34% | 35% | 34% | 35% |
| Other Income | 2 | 2 | 4 | 5 | 10 | 7 | 6 | 5 |
| Interest | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Profit before tax | 62 | 38 | 58 | 44 | 60 | 62 | 63 | 54 |
| Tax % | 21% | 24% | 24% | 29% | 21% | 23% | 23% | 25% |
| Net Profit | 49 | 29 | 44 | 31 | 47 | 48 | 49 | 41 |
| EPS in Rs | 128.13 | 2.95 | 4.54 | 3.17 | 4.71 | 4.2 | 4.33 | 3.59 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 24%
- 3 Years
- 14%
- TTM
- 24%
- 10 Years
- —
- 5 Years
- 39%
- 3 Years
- 40%
- TTM
- 20%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 32%
- 3 Years
- 32%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Sudeep Pharma | ₹ 1,124.00 | ₹ 10,901 Cr. | 69.2x | 12.3x | 25% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Sujit Jaysukh Bhayani
- Executive Chairman, Managing Director
- Ketan Jagdishchandra Vyas
- Chief Financial Officer
- Dimple Ashwinbhai Mehta
- Compliance Officer, Company Secretary
- Shanil Sujit Bhayani
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.